FDA Moves to Restrict Mass-Marketed Compounded GLP-1 Weight Loss Products
Feb 13, 2026
The FDA announced plans to restrict non-FDA-approved compounded GLP-1 drugs mass-marketed as alternatives to approved weight loss medications, citing safety concerns and misleading advertising practices.